William Reinsch, president of the National Foreign Trade Council (NFTC), expects Congress to vote on the Trans-Pacific Partnership (TPP) deal in April or May next year.» Read More
Drug stocks could take a hit if Hillary Clinton and others take action on the issue of prescription drug costs.
Michael Yee, BioTech Analyst, RBC Capital Markets, discusses costs in the biotech sector and what a Clinton White House would mean to the industry.
CNBC's Bertha Coombs reports on the hit to biotech stocks after Hillary Clinton's tweet criticizing drug price gouging.
Hillary Clinton is criticizing drug price gouging, after news a drug company hiked the price of one of its drugs by 5,000 percent overnight, with CNBC's Meg Tirrell.
Hillary Clinton is criticizing drug price gouging, reports CNBC's Meg Tirrell.
The iShares Nasdaq Biotechnology ETF took a visible leg down after the 10:56 a.m. ET tweet by the presidential candidate.
The "Fast Money" traders look at the areas you should be watching going into the new week.
Surgeons may soon plan out their operations with personalized 3-D printed replicas of their patient's organs.
Knox Singleton, Inova CEO, and Mark Bertolini, Aetna chairman & CEO, discuss ways to cut the costs of health care by changing the current model.
Mark Bertolini, Aetna chairman & CEO, weighs in on what the U.S. health care system will likely look like in the year 2035.
Knox Singleton, Inova CEO, and Mark Bertolini, Aetna chairman & CEO, share their thoughts on how the combination of biology and big data may be able to help predict women at risk of preterm births.
Knox Singleton, Inova CEO, discusses how genetic testing may be able to help people detect health issues before they happen and potentially extend life expectancy rates.
George Barrett, Cardinal Health CEO, and Mark Bertolini, Aetna chairman & CEO, talks about creating community-based models to take care of patients after hospital discharge. Also Bertolini shares ways to keep healthier. Sitting is the new smoking, says Bertolini.
We are going to see payment structures tied to some kind of value basis, says George Barrett, Cardinal Health CEO, discussing the way payment models will likely change in the future.
Joe Papa, Perrigo chairman & CEO, talks about Mylan's hostile bid for Perrigo and why he wants shareholders to reject the offer.
Despite some shakiness in the last month, the biotech sector offers some buying opportunities, "Fast Money" traders said.
A so-called female Viagra may have received FDA approval, but the patients it may actually help could be limited, Dr. Lisa Dabney says.
Kyle Bass, Hayman Capital Management founder and managing partner, discusses the criticism he is facing as he takes on drug patents.
David Seaburg, Cowen & Company, and Craig Johnson, Piper Jaffray & Co, discuss biotech, a formerly hot sector that's down more than 7 percent in a month.
The Food and Drug Administration will decide the fate of a drug to treat low libido in women by Tuesday.
Get the best of CNBC in your inbox